Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2019 | Pages:
185 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global irritable bowel syndrome treatment market size is expected to reach USD 3.3 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a 10.1% CAGR during the forecast period. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market. IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient's professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing. Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient's professional and personal activities, and usually limits an individual's potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life. Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females. Further key findings from the report suggest: • IBS-C was the largest revenue generating segment by type in 2018 due to growing prevalence and increasing uptake of drugs such as Linzess/Constella and Amitiza • Linzess/Constella led the global IBS treatment market by product in 2018 due to increasing adoption of the product in major regions such as U.S., Germany, U.K., Italy, Spain, and Japan • North America was estimated to be the largest revenue generating region in 2018, followed by Europe. Major factors contributing to its dominant share are presence of key market players, high patient awareness, strong presence of novel products, and well-established healthcare infrastructure • Europe is projected to be the fastest growing region over the forecast period. Rising commercialization of products and presence of a large target population are driving the IBS treatment market • Some of the major players are Allergan; Ironwood Pharmaceuticals, Inc.; Astellas Pharma, Inc.; AstraZeneca; Takeda Pharmaceutical Company Limited; Sebela Pharmaceuticals Inc.; Synthetic Biologics, Inc.; Ardelyx; and Bausch Health • Players have bene adopting strategies such as product extension, product development, regional expansion, and mergers and acquisitions to increase their market share. Bausch Health acquired Salix Pharmaceuticals in April 2015 to expand its portfolio with a focus on gastrointestinal drugs.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources & Third party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Irritable Bowel Syndrome Treatment Market Variables, Trends & Scope
3.1. Irritable Bowel Syndrome Treatment Market Lineage outlook
3.1.1. IBD market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Regulatory Framework
3.3.1. Reimbursement framework
3.3.2. Standards & compliances
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increase in geriatric population
3.4.1.2. Increasing prevalence of IBS
3.4.2. Market restraint analysis
3.4.2.1. Less awareness about the symptoms
3.5. Irritable Bowel Syndrome Treatment Market Analysis Tools
3.5.1. Industry analysis - Porter's
3.5.1.1. Supplier power (Moderate due to requirement of high-quality raw materials)
3.5.1.2. Buyer power (Low due to limited number of established providers)
3.5.1.3. Substitution threat (Moderate due to high prices)
3.5.1.4. New entrants' threat (High as the market is underserved)
3.5.1.5. Competitive rivalry (Moderate due to presence of few key players)
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Environmental landscape
3.5.2.3. Social landscape
3.5.2.4. Technology landscape
3.5.2.5. Legal landscape
3.5.3. Major deals & strategic alliances analysis
3.5.3.1. Joint ventures
3.5.3.2. Mergers & acquisitions
3.5.3.3. Licensing & partnership
3.5.3.4. Technology collaborations
3.5.3.5. Strategic divestments
Chapter 4. Irritable Bowel Syndrome Treatment Market - Competitive Analysis
4.1. Recent Developments & Impact Analysis, by Key Market Participants
4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3. Vendor Landscape
4.3.1. List of key distributors and channel partners
4.3.2. Key company market share analysis, 2018
4.4. Public Companies
4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.4.2. Company market share
4.4.3. Competitive dashboard analysis
4.4.4. Market differentiators
4.4.5. Synergy analysis: Major deals & strategic alliances
4.5. Private Companies
4.5.1. List of key emerging companies
4.5.2. Regional network map
4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Irritable Bowel Syndrome Treatment Market: Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Type Market Share Analysis, 2018 & 2026
5.3. Irritable Bowel Syndrome Treatment Market, by Type, 2014 to 2026
5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
5.4.1. IBS-C
5.4.1.1 IBS-C market, 2014 - 2026 (USD Million)
5.4.1.2 Linzess/Constella
5.4.1.2.1 Linzess/Constella market, 2014 - 2026 (USD Million)
5.4.1.3 Amitiza
5.4.1.3.1 Amitiza market, 2014 - 2026 (USD Million)
5.4.1.4 Others
5.4.1.4.1 Others market, 2014 - 2026 (USD Million)
5.4.2. IBS-D
5.4.2.1 IBS-D market, 2014 - 2026 (USD Million)
5.4.2.2 Xifaxan
5.4.2.2.1 Xifaxan market, 2014 - 2026 (USD Million)
5.4.2.3 Viberzi
5.4.2.3.1 Viberzi market, 2014 - 2026 (USD Million)
5.4.2.4 Others
5.4.2.4.1 Others market, 2014 - 2026 (USD Million)
Chapter 6. Irritable Bowel Syndrome Treatment Market: Product Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Product Market Share Analysis, 2018 & 2026
6.3. Irritable Bowel Syndrome Treatment Market, by Product, 2014 to 2026
6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
6.4.1. Xifaxan
6.4.1.1 Xifaxan market, 2014 - 2026 (USD Million)
6.4.2. Linzess/Constella
6.4.2.1 Linzess/Constella market, 2014 - 2026 (USD Million)
6.4.3. Viberzi
6.4.3.1 Viberzi market, 2014 - 2026 (USD Million)
6.4.4. Amitiza
6.4.4.1 Amitiza market, 2014 - 2026 (USD Million)
6.4.5. Others
6.4.5.1 Others market, 2014 - 2026 (USD Million)
Chapter 7 Irritable Bowel Syndrome Treatment Market: Regional Estimates & Trend Analysis, by Product, Test Location, Technology, & Application
7.1 Irritable Bowel Syndrome Treatment Market: Regional Movement Analysis, 2018 & 2026
7.2 Irritable Bowel Syndrome Treatment Market: Leading Players, 2018:
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4 North America
7.4.1 North America market, 2014 - 2026 (USD Million)
7.4.2 U.S.
7.4.2.1 U.S. market, 2014 - 2026 (USD Million)
7.4.3 Canada
7.4.3.1 Canada market, 2014 - 2026 (USD Million)
7.5. Europe
7.5.1 Europe market, 2014 - 2026 (USD Million)
7.5.2 U.K.
7.5.2.1 U.K. market, 2014 - 2026 (USD Million)
7.5.3 Germany
7.5.3.1 Germany market, 2014 - 2026 (USD Million)
7.5.4 Italy
7.5.4.1 Italy market, 2014 - 2026 (USD Million)
7.5.5 Spain
7.5.5.1 Spain market, 2014 - 2026 (USD Million)
7.6 Asia Pacific
7.6.1 Asia Pacific market, 2014 - 2026 (USD Million)
7.6.2 Japan
7.6.2.1 Japan market, 2014 - 2026 (USD Million)
7.6.3 China
7.6.3.1 China market, 2014 - 2026 (USD Million)
7.7 Latin America
7.7.1 Latin America market, 2014 - 2026 (USD Million)
7.7.2 Brazil
7.7.2.1 Brazil market, 2014 - 2026 (USD Million)
7.7.3 Mexico
7.7.3.1 Mexico market, 2014 - 2026 (USD Million)
7.8 MEA
7.8.1 MEA market, 2014 - 2026 (USD Million)
7.8.2 South Africa
7.8.2.1 South Africa market, 2014 - 2026 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Heat Map Analysis of Private Companies
8.2.1 Company size
8.2.2 Distribution network
8.2.3 Product portfolio
8.2.4 Segment coverage
8.2.5 Geographic presence
8.2.6 Collaborations
8.2.7 Conclusion
8.3 Ironwood Pharmaceuticals, Inc.
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 Allergan
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 Astellas Pharma, Inc.
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Takeda Pharmaceutical Company Limited
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 AstraZeneca
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 Sebela Pharmaceuticals Inc.
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Product benchmarking
8.8.4 Strategic initiatives
8.9 Synergy Pharmaceuticals Inc.
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 Synthetic Biologics, Inc.
8.10.1 Company overview
8.10.2 Product benchmarking
8.10.3 Strategic initiatives
8.11 Bausch Health
8.11.1 Company Overview
8.11.2 Financial performance
8.11.3 Product benchmarking
8.11.4 Strategic initiatives
8.12 Ardelyx
8.12.1 Company overview
8.12.2 Financial performance
8.12.3 Product benchmarking
8.12.4 Strategic initiatives
List of Tables TABLE 1 Country share estimation TABLE 2 North America irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 3 North America irritable bowel syndrome treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 4 U.S. irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 5 U.S. irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 6 Canada irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 7 Canada irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 8 Europe irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 9 Europe irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 10 U.K. irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 11 U.K. irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 12 Germany irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 13 Germany irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 14 Italy irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 15 Italy irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 16 Spain irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 17 Spain irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 18 Asia Pacific irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 19 Asia Pacific irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 20 Japan irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 21 Japan irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 22 China irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 23 China irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 24 Latin America irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 25 Latin America irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 26 Brazil irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 27 Brazil irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 28 Mexico irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 29 Mexico irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 30 MEA irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million) TABLE 31 MEA irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million) TABLE 32 South Africa irritable bowel syndrome treatment treatment market estimates and forecasts, by technology, 2014 - 2026 (USD Million) TABLE 33 South Africa PCR market estimates and forecasts, by type, 2014 - 2026 (USD Million)
List of Figures FIG. 1 Market research process FIG. 2 Information procurement FIG. 3 Market summary, 2018 FIG. 4 Market trends & outlook FIG. 5 Market segmentation & scope FIG. 6 Market driver relevance analysis (Current & future impact) FIG. 7 Market restrain relevance analysis (Current & future impact) FIG. 8 Penetration & growth prospect mapping FIG. 9 SWOT analysis, by factor (political & legal, economic and technological) FIG. 10 Porter's five forces analysis FIG. 11 Irritable bowel syndrome treatment market type outlook key takeaways FIG. 12 Irritable bowel syndrome treatment market: Type movement analysis FIG. 13 Global IBS-C market, 2014 - 2026 (USD Million) FIG. 14 Global IBS-D market, 2014 - 2026 (USD Million) FIG. 15 Irritable bowel syndrome treatment market product outlook: Key takeaways FIG. 16 Irritable bowel syndrome treatment market: Product movement analysis FIG. 17 Global Xifaxan market, 2014 - 2026 (USD Million) FIG. 18 Global Linzess/Constella market, 2014 - 2026 (USD Million) FIG. 19 Global Amitiza market, 2014 - 2026 (USD Million) FIG. 20 Global Viberzi market, 2014 - 2026 (USD Million) FIG. 21 Global others market, 2014 - 2026 (USD Million) FIG. 22 Regional market place: Key takeaways, 2018 FIG. 23 Regional outlook, 2018 & 2026 FIG. 24 North America irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 25 U.S. irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 26 Canada irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 27 Europe irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 28 U.K. irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 29 Germany irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 30 Spain irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 31 Italy irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 32 Asia Pacific irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 33 Japan irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 34 China irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 35 Latin America irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 36 Brazil irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 37 Mexico irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 38 MEA irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 39 South Africa irritable bowel syndrome treatment market, 2014 - 2026 (USD Million) FIG. 40 Strategy framework FIG. 41 Participant categorization
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
